It seems like ages since President Trump castigated drug company executives for “getting away with murder” and promised to take on the powerful pharma lobby.

While the spotlight has shifted (and the threat of a crackdown has dimmed), the pharma industry still has plenty on its plate. The man charged with pushing the industry’s agenda is Stephen J. Ubl, the president and CEO of the PhRMA trade group. He stopped by the STAT offices in Boston this week to talk about his plans — and the challenges he’s confronting. Here are the highlights:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You give front page space to Big Pharma’s highest paid Liar? And you have some rookie do the “interview?” Did Ed Silverman throw up? This is not journalism, this is pandering to advertisers. Shame on WHOEVER thought this was a good idea!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy